Loading
Utah Medical Products Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CORNWELL KEVIN L, was filed 15 Aug 2011.
Utah Medical Products Inc: what insiders have been doing
Utah Medical Products Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Utah Medical Products Inc. The previous disclosure was published on 5 September 2025.
The full history, which starts in 2006, counts 6 purchases against 153 sales. The 10-K for the year ended 31 December 2025 shows 38.5 m USD of revenue and 11.3 m USD of net income.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
268
Thresholds
n/a
Buy Volume
€104,827
6 ops. · all time
Sell Volume
€12M
153 ops. · all time
Since the insiders bought
- +31.8%Entry US$25.70 · Close at T+365 US$33.88
- -4.1%Entry US$27.82 · Close at T+365 US$26.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,983 of 26,290 companies
67.6
score / 100
Value54
Quality82
FCF yld6.0%
Earn yld4.8%
EV/EBITDA16.5x
ROE8.8%
Gross mgn57%
Net mgn29%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$74.71
Analyst consensus
Income statement
RevenueUS$38.5M
Gross profitUS$22M57% margin
EBITDAUS$14.4M37% margin
Net incomeUS$11.3M29.0% margin
Valuation
PER (trailing)22.8x
P/Book1.9x
Beta0.39
Balance sheet & cash
Market capUS$237.1M
Total debtUS$225k
Free Cash FlowUS$14.3M
Debt / Equity0%
Profitability & ownership
ROE8.8%
ROA6.1%
% insiders7.2%
% institutions76.6%
Last declaration on 5 September 2025
Declarations268 total
50 shares@ US$62.753.0% of flowCommon StockSEC:0001733614-25-000002:0
100 shares@ US$60.343.0% of flowCommon StockSEC:0001733614-25-000001:0
50 shares@ US$71.613.7% of flowCommon StockSEC:0001733614-24-000002:0
225 shares@ US$69.728.3% of flowCommon StockSEC:0001733614-24-000001:0
60 shares@ US$94.315.8% of flowCommon StockSEC:0001733614-23-000004:0
700 shares@ US$93.4734.9% of flowCommon StockSEC:0001733614-23-000003:0
150 shares@ US$92.507.5% of flowCommon StockSEC:0001733614-23-000002:0
500 shares@ US$89.997410.6% of flowCommon StockSEC:0001733614-23-000001:0
500 shares@ US$74.6418.6% of flowCommon StockSEC:0001733614-22-000009:1
366 shares@ US$101.8839.6% of flowCommon StockSEC:0001733614-22-000009:0
449 shares@ US$90.8122.6% of flowCommon StockSEC:0001733614-22-000008:0
161 shares@ US$90.008.0% of flowCommon StockSEC:0001733614-22-000007:0
40 shares@ US$92.502.1% of flowCommon StockSEC:0001733614-22-000006:0
65 shares@ US$88.946.5% of flowCommon StockSEC:0001733614-22-000005:0
250 shares@ US$88.9812.1% of flowCommon StockSEC:0001733614-22-000003:0
2,000 shares@ US$85.198340.9% of flowCommon StockSEC:0001733614-22-000002:0
500 shares@ US$98.9410.9% of flowCommon StockSEC:0001733614-22-000001:0
62 shares@ US$50.721.6% of flowCommon StockSEC:0001733614-21-000011:0
4,900 shares@ US$126.4124.3% of flowCommon StockSEC:0001733614-21-000010:1
100 shares@ US$125.01100.0% of flowCommon StockSEC:0001733614-21-000010:0
2,000 shares@ US$124.75100.0% of flowCommon StockSEC:0001733614-21-000009:0
1,249 shares@ US$111.065.9% of flowCommon StockSEC:0001733614-21-000008:1
751 shares@ US$111.062518.6% of flowCommon StockSEC:0001733614-21-000008:0
62 shares@ US$49.181.7% of flowCommon StockSEC:0001733614-21-000006:1
687 shares@ US$58.5022.2% of flowCommon StockSEC:0001733614-21-000006:2
25 of 268 declarations
About Utah Medical Products Inc
Utah Medical Products, Inc. (UTMD) is a U.S.-based medical device company listed on the NASDAQ in the United States. Headquartered in Midvale, Utah, UTMD focuses on specialized disposable and reusable devices used in critical care settings, with a business model centered on niche clinical applications rather than broad commodity volume. The company was formed as a Utah corporation in 1978 and completed a public stock offering in 1982, giving it a long operating history and a reputation built over decades in regulated healthcare markets. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf))
UTMD’s core commercial strength lies in women’s health and neonatal care, alongside blood pressure monitoring and other specialty hospital products. The company groups its revenues into four main categories: obstetrics; gynecology/electrosurgery/urology; neonatal; and blood pressure monitoring and accessories. Its portfolio includes the Filshie Clip System for female tubal ligation, neonatal products such as DISPOSA-HOOD, DELTRAN and GESCO-branded catheters and accessories, plus blood pressure monitoring kits used in hospital and NICU settings. In 2024, gynecology/electrosurgery/urology was the largest revenue category, followed by blood pressure monitoring, neonatal, and obstetrics. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf))
Read moreShow less
From a competitive standpoint, UTMD is best understood as a specialized, clinically oriented manufacturer with proprietary products, a global installed base, and a strong emphasis on quality, regulatory compliance and procedure-specific design. The company sells directly to end users and through distributors, and it also manufactures components and finished devices on a subcontract basis for other medical-device businesses. Outside the U.S., UTMD has direct or indirect commercial reach in Canada, the United Kingdom, France, Ireland, Australia and New Zealand, and management states that it has representation across major developed markets as well as many developing markets through roughly 200 distributors. That global footprint helps diversify demand, even though the business remains relatively concentrated in a limited number of product families. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf))
Recent company updates have been shaped by softer operating trends and capital returns to shareholders. In its 2025 quarterly releases, UTMD reported lower revenue versus the prior year, with the decline driven mainly by reduced OEM sales to PendoTECH. Even so, the company continued to post solid profitability, with margins remaining relatively high for the industry. In its January 29, 2026 year-end release, UTMD said it did not meet its beginning-of-year 2025 projections, but still ended the year with $85.8 million in cash, after paying $4.0 million in dividends and repurchasing 4.5% of its shares for $8.4 million. For investors, UTMD therefore looks like a defensive, cash-generative NASDAQ healthcare name with a modest growth profile, a specialized product mix, and meaningful exposure to litigation and customer-concentration risks. ([utahmed.com](https://www.utahmed.com/pr/UTMD-PR072425.pdf))
